U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H21NO3.H2O
Molecular Weight 317.3795
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CODEINE

SMILES

O.COC1=C2O[C@H]3[C@@H](O)C=C[C@H]4[C@H]5CC(C=C1)=C2[C@@]34CCN5C

InChI

InChIKey=WRRSFOZOETZUPG-FFHNEAJVSA-N
InChI=1S/C18H21NO3.H2O/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;/h3-6,11-13,17,20H,7-9H2,1-2H3;1H2/t11-,12+,13-,17-,18-;/m0./s1

HIDE SMILES / InChI
Molecular Formula C18H21NO3
Molecular Weight 299.3642
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Codeine is an opiate used to manage mild to moderate pain severe enough to require an opioid. Codeine is a selective agonist for the mu opioid receptor and has an affinity to delta and kappa-opioid receptors. In some countries, this drug is regulated under various narcotic control laws, because its chronic use can cause physical dependence. In others, it is available without a medical prescription in combination with paracetamol.

CNS Activity

Approval Year

1921
1468
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 6.1 µM [EC50]
Kappa-type opioid receptor
61
Target ID: P41145
Gene ID: 4986.0
Gene Symbol: OPRK1
Target Organism: Homo sapiens (Human)
Agonist
2752
Delta-type opioid receptor
46
Target ID: P41143
Gene ID: 4985.0
Gene Symbol: OPRD1
Target Organism: Homo sapiens (Human)
Agonist
2752
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
CAPITAL AND CODEINE

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
66.9 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1391681/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
145 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
229 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, intramuscular
dose: 60 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
93 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
242 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, intramuscular
dose: 60 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
53.5 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1391681/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MORPHINE-3-GLUCURONIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
66.9 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1391681/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
968 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1391681/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE-6-GLUCURONIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.61 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1391681/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
466 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
849 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, intramuscular
dose: 60 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
467 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
937 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, intramuscular
dose: 60 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.47 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1391681/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, intramuscular
dose: 60 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.7 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.9 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, intramuscular
dose: 60 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.71 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1391681/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MORPHINE-3-GLUCURONIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.47 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1391681/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.75 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1391681/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE-6-GLUCURONIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
75%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022402s000lbl.pdf
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
360 mg 1 times / day multiple, oral
Highest recorded dose
Dose: 360 mg, 1 times / day
Route: oral
Route: multiple
Dose: 360 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022402s000lbl.pdf
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022402s000lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022402s000lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946

inhibitor
2252
inhibitor
2438
substrate
1388

inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
OCT1
620

UGT2B7
197

CYP19A1
429

CYP1A2
2153
UGT2B7
456

UGT1A3
470

UGT1A1
479

UGT1A4
399

OCT1
393

UGT2B4
278

UGT1A8
323

UGT1A10
331

P-gp
2052

UGT2B15
236
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2D6
2546
 inconclusive [IC50 35.7774 uM]
CYP19A1
430
 no
CYP1A2
2333
 no
CYP2C9
2497
 no
CYP3A4
2633
 no
UGT2B7
210
 unlikely [IC50 400 uM]
OCT1
656
 yes [IC50 10.5 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
UGT2B4
278
 major
UGT2B7
456
 major
P-gp
2052
 no
UGT1A10
331
 no
UGT1A3
470
 no
UGT1A4
399
 no
UGT1A8
323
 no
UGT2B15
236
 no
CYP2D6
1388
 yes
CYP3A4
1946
 yes
OCT1
393
 yes
UGT1A1
479
 yes
Morphine
12
UGT2B7
456
 yes
Morphine
12
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ABI Chem
AC1Q4DTD
Alfa Chemistry
170301
Alfa Chemistry
ACM52453040
AN PharmaTech
AN-23899
Angene
AGN-PC-0U9ZUU
Aurora Fine Chemicals LLC
A17.876.233
http://online.aurorafinechemicals.com/info?ID=A17.876.233
Avantor Inc
75835-236
https://us.vwr.com/store/product/21998648/exempted-drug-of-abuse-reference-standards-restek
Changzhou Highassay Chemical Co., Ltd
my_sub1415
Chemieliva Pharmaceutical Co., Ltd
PBCM0821173
ChemMol
30101025
http://www.chemmol.com/chemmol/30101025.html
ChemMol
49416695
http://www.chemmol.com/chemmol/49416695.html
ChemMol
99138769
http://www.chemmol.com/chemmol/99138769.html
Clearsynth
CS-T-56966
http://www.clearsynth.com/en/CST56966.html
Compound Cloud
21155870
Compound Cloud
24892867
Compound Cloud
5284371
Compound Cloud
5362471
Compound Cloud
6321303
eMolecules
193733897
Hangzhou APIChem Technology
AC-11114
HongKong Chemhere
SCA54117
IBScreen
BB_NC-00138
IBScreen
STOCK1N-42851
LGC Standards
LGCAMP0004.10-01
https://www.lgcstandards.com/US/en/p/LGCAMP0004.10-01
LGC Standards
LGCAMP0004.10-02
https://www.lgcstandards.com/US/en/p/LGCAMP0004.10-02
LGC Standards
LGCFOR0004.10
https://www.lgcstandards.com/US/en/p/LGCFOR0004.10
LGC Standards
MM0004.10
https://www.lgcstandards.com/US/en/p/MM0004.10
mcule
MCULE-4129237460
mcule
MCULE-6243921692
Parchem
87121
https://www.parchem.com/chemical-supplier-distributor/Codeine-Alkaloid-087121.aspx
Parchem
87123
https://www.parchem.com/chemical-supplier-distributor/Codeine-USP-087123.aspx
Sigma-Aldrich
C-006_CERILLIAN
https://www.sigmaaldrich.com/catalog/product/cerillian/c006?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
C1653_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/c1653?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
Y0000722_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/y0000722?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma Aldrich
C1653|SIAL
Sigma Aldrich
C3539|SIAL
Sigma Aldrich
C5901|SIAL
Sigma Aldrich
Y0000722
Sigma Aldrich
Y0000722|SIAL
Smolecule
S627560
https://www.smolecule.com/products/s627560
Tetrahedron
TS63993
Tetrahedron
TS80953
Toronto Research Chemicals
C634075
Toronto Research Chemicals
C634080
Toronto Research Chemicals
KIT0410
Toronto Research Chemicals
KIT2460
Yick-Vic Chemicals & Pharmaceuticals (HK) Ltd.
PH-1498A
ZINC
ZINC000003806721
http://zinc15.docking.org/substances/ZINC000003806721
PubMed

PubMed

TitleDatePubMed
LC method for the analysis of paracetamol, caffeine and codeine phosphate in pharmaceutical preparations.
2001-12
The role of adrenal corticosteroids in induction of micronuclei by morphine.
2001-11-15
Nutritional effects of surgical and medical treatment for short bowel syndrome.
2001-11-02
Scalp nerve blocks decrease the severity of pain after craniotomy.
2001-11
Concentration ratios of morphine to codeine in blood of impaired drivers as evidence of heroin use and not medication with codeine.
2001-11
Endogenous morphine and codeine. Possible role as endogenous anticonvulsants.
2001-10-12
Drug contamination of US paper currency.
2001-10-01
Predictors for completing an inpatient detoxification program among intravenous heroin users, methadone substituted and codeine substituted patients.
2001-10-01
Novel dynamic polymer coating for capillary electrophoresis in nonaqueous methanolic background electrolytes.
2001-10
Seizures with intravenous codeine phosphate.
2001-10
Incorporation of selegiline metabolites into hair after oral selegiline intake.
2001-10
Analysis of morphine and codeine in samples adulterated with Stealth.
2001-10
Detection of opiate use in a methadone maintenance treatment population with the CEDIA 6-acetylmorphine and CEDIA DAU opiate assays.
2001-10
Ropivacaine with or without clonidine improves pediatric tonsillectomy pain.
2001-10
Experience with urine drug testing by the Correctional Service of Canada.
2001-09-15
Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999.
2001-09
Community pharmacists' experience of over-the-counter medicine misuse in Scotland.
2001-09
Cetirizine inhibits skin reactions but not mediator release in immediate and developing late-phase allergic cutaneous reactions. A double-blind, placebo-controlled study.
2001-09
Rofecoxib versus codeine/acetaminophen in postoperative dental pain: a double-blind, randomized, placebo- and active comparator-controlled clinical trial.
2001-09
Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial.
2001-09
Blind trials of an onsite saliva drug test for marijuana and opiates.
2001-09
[Weak opioids].
2001-09
[Strong opioids].
2001-09
Concentration ratios of codeine-to-morphine in plasma after a single oral dose (100 mg) of codeine phosphate.
2001-09
Detection of non-prescription heroin markers in urine with liquid chromatography-atmospheric pressure chemical ionization mass spectrometry.
2001-09
Pain control in medical abortion.
2001-09
Engineering novel biocatalytic routes for production of semisynthetic opiate drugs.
2001-09
Can standard open pediatric urological procedures be performed on an outpatient basis?
2001-09
Precipitated withdrawal following codeine administration is dependent on CYP genotype.
2001-08-17
From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial.
2001-08-15
Heroin use by motorists in Sweden confirmed by analysis of 6-acetylmorphine in urine.
2001-08-14
Laboratory analysis of remotely collected oral fluid specimens for opiates by immunoassay.
2001-08-14
Prescribing limitations.
2001-08-11
[Paracetamol-codeine induced hepatic colic].
2001-08-02
Randomized placebo controlled trial of lofexidine hydrochloride for chronic pelvic pain in women.
2001-08
Simultaneous determination of codeine and ethyl morphine HCL in tablet formulations using LC.
2001-08
Sticky business: patterns of procurement and misuse of prescription cough syrup in Houston.
2001-07-31
Head-column field-amplified sample stacking in presence of siphoning. Application to capillary electrophoresis-electrospray ionization mass spectrometry of opioids in urine.
2001-07-27
Use of beta-cyclodextrin in the capillary zone electrophoretic separation of the components of clandestine heroin preparations.
2001-07-27
Opiate-sensitivity: clinical characteristics and the role of skin prick testing.
2001-07
Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis.
2001-07
[Information on preparations containing codeine].
2001-06-20
[Chronic pain in geriatrics].
2001-06
Effect of apical trephination on postoperative pain and swelling in symptomatic necrotic teeth.
2001-06
Codeine phosphate in paediatric medicine.
2001-03
Codeine phosphate in children: time for re-evaluation?
2001-03
Effect of penicillin on postoperative endodontic pain and swelling in symptomatic necrotic teeth.
2001-02
Effect of prophylactic amoxicillin on endodontic flare-up in asymptomatic, necrotic teeth.
2001-01
Over-the-counter medications for acute cough in children and adults in ambulatory settings.
2001
Dystonia as acute adverse reaction to cough suppressant in a 3-year-old girl.
2001
Patents

Patents

05869669
14
08337890
16
08710069
12
08790700
16
JP2002104963A
12
JP2002511777A
420
JP2006520379A
75
JP2009520033A
20
JP2011507842A
17
JP4804361B2
32
JPH00286794A
24
JPS5323998A
14
JPS572288A
16

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:45:32 GMT 2025
Edited
by admin
on Mon Mar 31 17:45:32 GMT 2025
Record UNII
Q830PW7520
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CODEINE
EP   MART.   USP   VANDF  
Common Name English
CODEINE MONOHYDRATE
WHO-DD   WHO-IP  
Preferred Name English
LEAN
Common Name English
MORPHINAN-6-OL, 7,8-DIDEHYDRO-4,5-EPOXY-3-METHOXY-17-METHYL-, MONOHYDRATE, (5.ALPHA.,6.ALPHA.)-
Systematic Name English
CODEINUM
HPUS  
Common Name English
CODEINUM MONOHYDRICUM [WHO-IP LATIN]
Common Name English
CODEINE [MART.]
Common Name English
7,8-Didehydro-4,5?-epoxy-3-methoxy-17-methylmorphinan-6?-ol monohydrate
Systematic Name English
CODEINE [USP MONOGRAPH]
Common Name English
CODEINE MONOHYDRATE [EP MONOGRAPH]
Common Name English
DEA NO. 9050
Common Name English
CODEINE MONOHYDRATE [WHO-IP]
Common Name English
CODEINE [VANDF]
Common Name English
CODEINUM [HPUS]
Common Name English
Codeine monohydrate [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-ATC N02AA79
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
WHO-ATC N02AJ06
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 2.2
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
WHO-VATC QN02AA79
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
WHO-ATC N02AJ08
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
CFR 21 CFR 341.14
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
CFR 21 CFR 1308.15
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
CFR 21 CFR 341.74
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
WHO-ATC N02AA59
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
DEA NO. 9050
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
CFR 21 CFR 290.2
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
WHO-ATC R05DA04
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
WHO-ATC N02AJ07
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
NCI_THESAURUS C1657
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
WHO-VATC QR05DA04
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
NDF-RT N0000175690
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
WHO-VATC QN02AA59
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
LIVERTOX NBK548359
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
Code System Code Type Description
WHO INTERNATIONAL PHARMACOPEIA
CODEINE
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY Description: Colourless crystals or a white, crystalline powder; odourless.Solubility: Slightly soluble in water; freely soluble in ethanol (~750 g/l) TS and ether R.Category: Antitussive; analgesic.Storage: Codeine monohydrate should be kept in a tightly closed container, protected from light.Additional information: Codeine monohydrate effloresces slowly in dry air.
IUPHAR
1673
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY
EPA CompTox
DTXSID20209391
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY
WIKIPEDIA
CODEINE
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY
ChEMBL
CHEMBL485
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY
EVMPD
SUB26908
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY
NCI_THESAURUS
C383
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY
DRUG BANK
DB00318
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY
CHEBI
16714
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY
PUBCHEM
5362471
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY
SMS_ID
100000090266
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY
EVMPD
SUB13424MIG
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY
CHEBI
57871
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY
DAILYMED
Q830PW7520
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY
FDA UNII
Q830PW7520
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY
MESH
D003061
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY
RXCUI
2670
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY RxNorm
DRUG CENTRAL
725
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY
LACTMED
Codeine
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY
CAS
6059-47-8
Created by admin on Mon Mar 31 17:45:32 GMT 2025 , Edited by admin on Mon Mar 31 17:45:32 GMT 2025
PRIMARY
Related Record Type Details
Structure of CODEINE ANHYDROUS
PARENT -> SALT/SOLVATE
Structure of CODEINE ANHYDROUS
ANHYDROUS->SOLVATE
Related Record Type Details
Structure of MORPHINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CODEINONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of Thebaine
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 10-HYDROXYCODEINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ORIPAVINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CODEINE N-OXIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of NORCODEINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of Hydroxycodeinone
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2,2'-BISCODEINE
IMPURITY -> PARENT
Structure of 7,7-OXYBIS(4,5.ALPHA.-EPOXY-3-METHOXY-17-METHYL-6,7,8,14-TETRADEHYDROMORPHINAN-6-OL)
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 14-HYDROXYCODEINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3-O-(CODEIN-2-YL)MORPHINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of METHYLCODEINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966